Podcast: Play in new window | Download () | Embed
Subscribe: Apple Podcasts | Spotify | RSS
We chat with Adam Stoten, the chief operating officer of Oxford University Innovation, about vaccines – not just for covid but also one for tuberculosis he helped develop at a spinout – as well as the importance of REF, KEF and the Knowledge Exchange Concordat, and the success of LAB282. He also exclusively reveals what is next for him personally.